ClinicalTrials.gg
RecruitingNCT07410169Updated Sep 30, 2026

Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy

A Phase 2/3 interventional study of Hyperbaric oxygen treatment and Standard Care (in control arm) in Breast Cancer, CIPN - Chemotherapy-Induced Peripheral Neuropathy and Paclitaxel-induced Peripheral Neuropathy, sponsored by Guangdong Provincial People's Hospital. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Guangdong Provincial People's Hospital · Phase 2/3, Interventional, and Treatment

How we know

Updated Sep 30, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital — 13 open to participants now, 14 under way, 3 of them phase 3. Breast Neoplasms · Guangdong Provincial People's Hospital.

Planned enrollment
12th of 23
160 · median 160
Started
2026
with 1 other
Phase 2/3
2 of 24
1 open now
Primary completion
2027-12
later than 12 of 13 live
Registered
23rd of 24
by date

Among the 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital, this one is the 12th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2/3, reaches primary completion later than 12 of the 13 other live ones, and was the 23rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital, or all of them as a file.
02

Study summary

The goal of this research is to assess whether hyperbaric oxygen therapy can alleviate the symptoms of Nab-paclitaxel-induced peripheral neuropathy and improve patient-reported quality of life.

03

Conditions studied

  • Breast Cancer
  • CIPN - Chemotherapy-Induced Peripheral Neuropathy
  • Paclitaxel-induced Peripheral Neuropathy

Browse trials for

Keywords

  • Breast Cancer
  • paclitaxel-Induced Peripheral Neuropathy
  • Hyperbaric Oxygen Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. aged ≥ 18 years and ≤ 75 years, female
  2. early-stage breast cancer or locally advanced breast cancer
  3. Patients who have completed or neoadjuvant chemotherapy with nab-paclitaxel
  4. The patient developed nab-paclitaxel induced peripheral neuropathy (Nab-PIPN), as defined by meeting any of the following criteria: Patient Neurotoxicity Questionnaire (PNQ) score ≥ Grade B, (sensory and motor neuropathy) grade ≥ 1, or neuropathic pain score ≥ 4/10.
  5. The patient voluntarily participated in this study, provided written , and agreed to cooperate with follow-up assessments.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously taken drugs that may affect the evaluation of Nab-PIPN symptoms, such as duloxetine, venlafaxine, gabapentin, pregabalin, and amitriptyline.
  2. Patients with any other pathological conditions or diseases that could affect Nab-PIPN assessment, including alcoholic peripheral neuropathy, uremic peripheral neuropathy, diabetic peripheral neuropathy, thiamine deficiency-related peripheral neuropathy, and chronic axonal peripheral neuropathy of unknown etiology.
  3. Patients who have for hyperbaric oxygen therapy, including pulmonary disorders (severe , bullous lung disease, acute or chronic pulmonary infection, uncontrolled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear diseases (eustachian tube dysfunction, recurrent vertigo), and ocular conditions (retinal detachment).
  4. Patients with any disease history that may affect compliance, including severe mental disorders, cognitive impairment, substance abuse or addiction.
  5. Performance Status score \< 80
  6. Patients with any other conditions that the investigator deems unsuitable for participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    HBOT group

    hyperbaric oxygen intervention:Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, one per day for 90-120 minutes, for a total of 20-30 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA)

    Device: Hyperbaric oxygen treatment

  • Other
    Control group

    Standard care

    Other: Standard Care (in control arm)

Interventions

  • DeviceHyperbaric oxygen treatment

    Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, one per day for 90-120 minutes, for a total of 20-30 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA)

  • OtherStandard Care (in control arm)

    Standard care

06

What researchers measure

Primary outcomes

  1. EORTC QLQ-CIPN20 subscales

    Self-reported neuropathy was assessed with the European Organisation for the Research and Treatment of Cancer Quality of Life (EORTC QLQ) CIPN20, which contains 20 items divided into three subscales assessing sensory, motor and autonomic symptoms. Each item was scored on a scale ranging from 1 'not at all' to 4 'very much'. Scores were transformed to a 0-100 scale, with higher scores representing more complaints

    Time frame: baseline, after intervention (week 6) and 1 , 3 , 6 and 12month after the intervention ended.

Secondary outcomes

  1. NCI-CTCAE 5.0

    Patients will be assessed by professional physicians in accordance with the CTCAE Version 5.0 grading criteria. The evaluated items include peripheral sensory neuropathy, peripheral motor neuropathy, dysesthesia, paresthesia, myalgia, arthralgia, and neuralgia, each of which will be graded on a scale from Grade 0 to Grade 4

    Time frame: baseline, after intervention (week 6) and 1 , 3 , 6 and 12month after the intervention ended

  2. EORTC QLQ-C30

    QoL was assessed with the EORTC QLQ-C30, which contains five functional scales, a global health status/QoL scale, three symptoms scales and six single items. Each item was scored on a scale ranging from 1 'not at all' to 4 'very much', except for the global QoL scale that ranges from 1 'very poor' to 7 'excellent'. Scores were transformed to a 0-100 scale, where higher scores indicate better functional status and quality of life (QoL), whereas higher scores reflect more severe symptoms.

    Time frame: baseline, after intervention (week 6) and 1 , 3 , 6 and 12month after the intervention ended

  3. BPI-SF

    Patient-reported pain severity and functional interference was assessed using the well-validated Brief Pain Inventory-Short Form (BPI-SF). The Brief Pain Inventory-Short Form (BPI-SF) includes four items that assess average, worst, least, and current pain severity over the past 24 hours. Each pain severity item is rated on an 11-point numeric rating scale (0 = no pain; 10 = pain as bad as you can imagine). Moreover, seven BPI items-assessing interference with daily activities/functions-are scored using the same 11-point scale (0 = does not interfere; 10 = completely interferes), consistent with established methodology. The seven items were summed to obtain a total interference score.

    Time frame: baseline, after intervention (week 6) and 1 , 3 , 6 and 12month after the intervention ended

  4. Nerve Conduction Velocity

    Sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (SNCV) will be measured. The nerves measured included the tibial nerve, sural nerve, median nerve, and ulnar nerve.

    Time frame: baseline, after intervention (week 6) and 1 , 3 , 6 and 12month after the intervention ended

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

Of 43 non-industry phase 2/3 interventional studies under Breast Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 91. This study's planned 15 months is below that.

Counting every sponsor, half of 56 studies reached it within 57 months; a quarter within 32 and three quarters within 88.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Sep 2026, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 13, 2026
StartEst.
Sep 29, 2026was Jan 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
1 site added. Guangdong Provincial People's Hospital is now Recruiting
Show site
  • Guangdong Provincial People's Hospital · Guangzhou, China
Sep 30, 2026
Start date
Jan 31, 2026→Sep 29, 2026
Sep 30, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Guangdong Provincial People's Hospital · Guangzhou, ChinaContact 1•••@163.com · •••5689→g•••@126.com · •••3200Contact g•••@126.com · •••8086→none listed
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Recruiting
    1 site added. Guangdong Provincial People's Hospital is now Recruiting
    Show site
    • Guangdong Provincial People's Hospital · Guangzhou, China
    Start date Jan 31, 2026→Sep 29, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Guangdong Provincial People's Hospital · Guangzhou, ChinaContact 1•••@163.com · •••5689→g•••@126.com · •••3200Contact g•••@126.com · •••8086→none listed
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07410169
Responsible party
Kun Wang (Professor, Guangdong Provincial People's Hospital) — Principal investigator
First posted
Feb 13, 2026
Start date
Sep 29, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Kun Wang, PhD
Contact
gzwangkun@126.com
+8615989223200
Yingcong Lin, Master of Medicine
Contact
18666885689@163.com
+8618666885689
Kun Wang
principal investigator · Guangdong Provincial People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion